Tapan M. Kadia

The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 98 papers. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

The Lancet Haematology(2021)10.1016/s2352-3026(21)00192-7

N/A

5.0DataRank · unranked

178 citations

Patrick K. Reville, Gautam Borthakur, Musa Yılmaz, Steven M. Kornblau, Yesid Alvarado +13 more

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax

Cancer(2021)10.1002/cncr.33689

N/A

3.9DataRank · unranked

158 citations

Abhishek Maiti, Sanam Loghavi, Rasoul Pourebrahim, Tapan M. Kadia, Caitlin R. Rausch +14 more

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Advances(2021)10.1182/bloodadvances.2020003717

N/A

3.2DataRank · unranked

82 citations

Courtney D. DiNardo, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver +28 more

Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

Clinical Infectious Diseases(2020)10.1093/cid/ciaa358

N/A

3.1DataRank · unranked

77 citations

David McCue, Sebastian Wurster, Nathan P. Wiederhold, Marina Konopleva, Tapan M. Kadia +18 more

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

Journal of Clinical Oncology(2024)10.1200/jco.23.01911

N/A

2.7DataRank · unranked

152 citations

Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Lewis Nasr, Walid Macaron +19 more

Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

Blood Cancer Journal(2022)10.1038/s41408-021-00604-2

N/A

2.5DataRank · unranked

95 citations

Koichi Takahashi, Naval Daver, Abhishek Maiti, Gautam Borthakur, Sanam Loghavi +14 more

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants

American Journal of Hematology(2023)10.1002/ajh.27070

N/A

1.6DataRank · unranked

48 citations

Sanam Loghavi, Yoheved Gerstein, Alexandre Bazinet, Koji Sasaki, Kelly S. Chien +19 more

Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia

American Journal of Hematology(2021)10.1002/ajh.26122

N/A

1.4DataRank · unranked

25 citations

Abhishek Maiti, Courtney D. DiNardo, Sanam Loghavi, Naval Daver, Tapan M. Kadia +11 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

Nature Cancer(2024)10.1038/s43018-024-00811-3

N/A

0.878DataRank · unranked

37 citations

Divij Verma, Natalia Baran, Tushar D. Bhagat, Anna Skwarska, Alessia Lodi +42 more

A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia

Clinical Lymphoma Myeloma & Leukemia(2025)10.1016/j.clml.2025.05.013

N/A

0.344DataRank · unranked

8 citations

Elias Jabbour, Nicholas J. Short, Tapan M. Kadia, Naveen Pemmaraju, Koichi Takahashi +4 more

Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine

Leukemia & lymphoma/Leukemia and lymphoma(2021)10.1080/10428194.2021.1973675

N/A

0.308DataRank · unranked

5 citations

Abhishek Maiti, Courtney D. DiNardo, Wei Qiao, Jing Ning, Sanam Loghavi +13 more

Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms in blastic phase

Blood Advances(2025)10.1182/bloodadvances.2025016898

N/A

0.262DataRank · unranked

4 citations

Lucia Masárová, Christopher P. Mill, Christine Birdwell, Kaberi Das, Hanxi Hou +16 more

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies

American Journal of Hematology(2025)10.1002/ajh.70046

N/A

0.245DataRank · unranked

4 citations

Sanam Loghavi, Alexandre Bazinet, Álex Bataller, Ian Bouligny, Naval Daver +15 more

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

Blood Neoplasia(2025)10.1016/j.bneo.2025.100145

N/A

0.104DataRank · unranked

1 citations

Wei‐Ying Jen, Guillermo Montalban‐Bravo, Xuemei Wang, Sanam Loghavi, Sravanthi Lavu +15 more

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial

Cancer(2025)10.1002/cncr.35840

N/A

0.104DataRank · unranked

1 citations

Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Elias Jabbour +13 more

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements

Blood Cancer Journal(2021)10.1038/s41408-021-00557-6

N/A

0DataRank · unranked

99 citations

Jabra Zarka, Koji Sasaki, Wei Qiao, Daewoo Pak, Jing Ning +16 more

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

Blood(2021)10.1182/blood.2020010603

N/A

0DataRank · unranked

80 citations

Arda Durmaz, Carmelo Gurnari, Ashwin Kishtagari, Manja Meggendorfer, Cassandra M Kerr +19 more

Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia

American Journal of Hematology(2021)10.1002/ajh.26238

N/A

0DataRank · unranked

55 citations

Abhishek Maiti, Farhad Ravandi, Marina Konopleva, Naval Daver, Tapan M. Kadia +8 more

Ten‐day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity score‐matched analysis

Cancer(2021)10.1002/cncr.33814

N/A

0DataRank · unranked

51 citations

Courtney D. DiNardo, Wei Qiao, Tapan M. Kadia, Elias Jabbour, Caitlin R. Rausch +18 more

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Blood Advances(2021)10.1182/bloodadvances.2020003934

N/A

0DataRank · unranked

48 citations

Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval Daver, Tapan M. Kadia +7 more

Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

Blood Cancer Journal(2021)10.1038/s41408-021-00453-z

N/A

0DataRank · unranked

45 citations

Hagop M. Kantarjian, Farhad Ravandi, Elias Jabbour, Courtney D. DiNardo, Naval Daver +12 more

Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia

Blood(2021)10.1182/blood.2020010483

N/A

0DataRank · unranked

43 citations

Kiyomi Morita, Sanam Loghavi, Feng Wang, Ken Furudate, Yuya Sasaki +19 more

Impact of frontline treatment approach on outcomes of myeloid blast phase CML

Journal of Hematology & Oncology(2021)10.1186/s13045-021-01106-1

N/A

0DataRank · unranked

37 citations

Elias Jabbour, Ghayas C. Issa, Koji Sasaki, Farhad Ravandi, Abhishek Maiti +11 more

Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm

American Journal of Hematology(2021)10.1002/ajh.26417

N/A

0DataRank · unranked

37 citations

Marina Konopleva, Mrinal M. Patnaik, Elias Jabbour, Courtney D. DiNardo, Aref Al‐Kali +7 more

Maintenance Therapy in AML

Frontiers in Oncology(2021)10.3389/fonc.2020.619085

N/A

0DataRank · unranked

32 citations

Tapan M. Kadia, Patrick K. Reville

Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes

Cancer(2021)10.1002/cncr.33745

N/A

0DataRank · unranked

32 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Faezeh Darbaniyan, Elias Jabbour, Carlos E. Bueso‐Ramos +13 more

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

Leukemia(2021)10.1038/s41375-021-01240-2

N/A

0DataRank · unranked

31 citations

Danielle Hammond, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Nicholas J. Short +15 more

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

Blood Cancer Journal(2021)10.1038/s41408-021-00446-y

N/A

0DataRank · unranked

10 citations

Guillermo Montalban‐Bravo, Panagiotis Katsonis, Koji Sasaki, Caleb A. Class, Elias Jabbour +26 more

Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remission

Cancer(2021)10.1002/cncr.33409

N/A

0DataRank · unranked

10 citations

Hagop M. Kantarjian, Farhad Ravandi, Naval Daver, Xuemei Wang, Elias Jabbour +16 more

Contemporary outcomes for adults with AML requiring ICU admission.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.7025

N/A

0DataRank · unranked

4 citations

Koji Sasaki, Alexis Geppner, Fadi Haddad, Shehab Mohamed, Daniel Rivera +15 more

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms

Blood(2022)10.1182/blood.2021014956

N/A

0DataRank · unranked

140 citations

Veronica Guerra, James A. Kennedy, Yuanqing Yan, Joanne I. Hsu, Feng Wang +20 more

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

Leukemia(2022)10.1038/s41375-022-01707-w

N/A

0DataRank · unranked

82 citations

Naval Daver, Steffen Boettcher, Christopher P. Mill, Koji Sasaki, Christine Birdwell +11 more

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Advances(2022)10.1182/bloodadvances.2022008316

N/A

0DataRank · unranked

56 citations

Aram Bidikian, Sangeetha Venugopal, Marina Konopleva, Courtney D. DiNardo, Tapan M. Kadia +20 more

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01229-z

N/A

0DataRank · unranked

32 citations

Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron +18 more

Long-Term Outcomes among Adolescent and Young Adult Survivors of Acute Leukemia: A Surveillance, Epidemiology, and End Results Analysis

Cancer Epidemiology Biomarkers & Prevention(2022)10.1158/1055-9965.epi-21-1388

N/A

0DataRank · unranked

30 citations

Clark R. Andersen, Branko Cuglievan, David McCall, Philip J. Lupo, Susan K. Parsons +7 more

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

American Journal of Hematology(2022)10.1002/ajh.26451

N/A

0DataRank · unranked

23 citations

Koji Sasaki, Hagop M. Kantarjian, Naval Daver, Musa Yılmaz, Courtney D. DiNardo +13 more

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

Blood Advances(2022)10.1182/bloodadvances.2021006689

N/A

0DataRank · unranked

1 citations

Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J. Short +6 more

Major clinical response in a patient with leukemia cutis treated with the bromodomain inhibitor PLX51107 and azacitidine

Leukemia Research(2022)10.1016/j.leukres.2022.106884

N/A

0DataRank · unranked

1 citations

Alexandre Bazinet, Sanam Loghavi, Marina Konopleva, Kapil N. Bhalla, Naval Daver +10 more

Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e19028

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Naveen Pemmaraju, Guillermo Montalban‐Bravo, Kelly S. Chien, Naval Daver +12 more

Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1

Blood Cancer Journal(2023)10.1038/s41408-023-00826-6

N/A

0DataRank · unranked

55 citations

Christopher P. Mill, Christine Birdwell, John A. Davis, Kaberi Das, Steffen Boettcher +13 more

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience

Cancers(2023)10.3390/cancers15071983

N/A

0DataRank · unranked

33 citations

Amber Gibson, Jiasen He, David McCall, Michael Roth, César Núnêz +23 more

Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity

Blood Advances(2023)10.1182/bloodadvances.2022009391

N/A

0DataRank · unranked

29 citations

Tapan M. Kadia, Nicholas J. Short, Gautam Borthakur, Sa A. Wang, Wei Wang +22 more

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Blood Advances(2023)10.1182/bloodadvances.2022009632

N/A

0DataRank · unranked

24 citations

Faustine Ong, Farhad Ravandi, Graciela M. Nogueras‐González, Tapan M. Kadia, Naval Daver +15 more

Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1429

N/A

0DataRank · unranked

23 citations

Warren Fiskus, Naval Daver, Nathaniel R. Wilson, Farhad Ravandi, Guillermo Garcia‐Manero +19 more

Early mortality in acute myeloid leukemia with KMT2A rearrangement is associated with high risk of bleeding and disseminated intravascular coagulation

Cancer(2023)10.1002/cncr.34728

N/A

0DataRank · unranked

20 citations

Hagop M. Kantarjian, Nicholas J. Short, Wei Qiao, Jing Ning, Branko Cuglievan +12 more

Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era

American Journal of Hematology(2023)10.1002/ajh.27037

N/A

0DataRank · unranked

20 citations

Koji Sasaki, Aram Bidikian, Ghayas C. Issa, Tapan M. Kadia, Nitin Jain +11 more

Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation

American Journal of Hematology(2023)10.1002/ajh.26997

N/A

0DataRank · unranked

18 citations

Hagop M. Kantarjian, Naszrin Arani, Uday Popat, Álex Bataller, Koji Sasaki +19 more

Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression

Leukemia(2023)10.1038/s41375-023-02108-3

N/A

0DataRank · unranked

11 citations

Warren Fiskus, Tapan M. Kadia, Christopher P. Mill, Koji Sasaki, Naval Daver +13 more

Association between bariatric surgery and outcomes in chronic myeloid leukemia

Cancer(2023)10.1002/cncr.34725

N/A

0DataRank · unranked

11 citations

Hagop M. Kantarjian, Aram Bidikian, Elias Jabbour, Nicholas J. Short, Jing Ning +10 more

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1

Leukemia(2023)10.1038/s41375-023-01882-4

N/A

0DataRank · unranked

10 citations

Warren Fiskus, Kaberi Das, John A. Davis, Christine Birdwell, Tapan M. Kadia +11 more

Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept

Frontiers in Immunology(2023)10.3389/fimmu.2023.1249511

N/A

0DataRank · unranked

9 citations

Naval Daver, Myrna C. B. Godoy, Girish S. Shroff, Carol C. Wu, Luis F. Torre-Sada +19 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

Research Square(2023)10.21203/rs.3.rs-2518774/v1

N/A

0DataRank · unranked

7 citations

Courtney D. DiNardo, Tushar D. Bhagat, Natalia Baran, Alessia Lodi, Kapil Saxena +38 more

Ibrutinib, Fludarabine, Cyclophosphamide and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without Del(17p)/ TP53 Mutation: Six-Year Follow-up Analyses

Blood(2023)10.1182/blood-2023-188084

N/A

0DataRank · unranked

1 citations

Philip A. Thompson, Akhil Jain, Jan A. Burger, Alessandra Ferrajoli, Jayastu Senapati +27 more

Single-Cell Proteogenomics Analysis of AML Samples Treated with Decitabine and Venetoclax Reveals Divergent Treatment Escape Mechanisms

Blood(2023)10.1182/blood-2023-190400

N/A

0DataRank · unranked

1 citations

Zongrui Li, Abhishek Maiti, Tomoyuki Tanaka, Hidetaka Uryu, Ken Furudate +21 more

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Blood(2023)10.1182/blood-2023-182841

N/A

0DataRank · unranked

0 citations

Alexandre Bazinet, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Elias Jabbour +12 more

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Blood(2023)10.1182/blood-2023-188051

N/A

0DataRank · unranked

0 citations

Meixian Huang, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose +10 more

A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0028

N/A

0DataRank · unranked

47 citations

Sagar Lonial, Amanda F. Cashen, Manali Kamdar, Ian W. Flinn, Susan O’Brien +15 more

BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor

Blood(2024)10.1182/blood.2023022832

N/A

0DataRank · unranked

42 citations

Jessica Piel, Michael P. Collins, Murphy Hentemann, Branko Cuglievan, Christopher P. Mill +21 more

Sotatercept for anemia of myelofibrosis: a phase II investigator-initiated study

Haematologica(2024)10.3324/haematol.2023.284078

N/A

0DataRank · unranked

15 citations

Lucia Masárová, Naveen Pemmaraju, Sharon Bledsoe, Naval Daver, Elias Jabbour +19 more

Safety and long‐term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single‐center phase 1,2 trial

American Journal of Hematology(2024)10.1002/ajh.27254

N/A

0DataRank · unranked

5 citations

Kamal Alzahrani, Hagop M. Kantarjian, Denái R. Milton, Alison Gulbis, Koji Sasaki +18 more

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood(2024)10.1182/blood-2024-203706

N/A

0DataRank · unranked

5 citations

Jayastu Senapati, Sanam Loghavi, Patrick K. Reville, Bofei Wang, Tapan M. Kadia +21 more

Gemtuzumab Ozogamicin Added to Fludarabine, Cytarabine and G-CSF (FLAG-GO) Leads to Superior Molecular Response and Survival Outcomes Than Idarubicin (FLAG-IDA): 200 Patients Long-Term Follow up

Blood(2024)10.1182/blood-2024-211599

N/A

0DataRank · unranked

3 citations

H. Kantarjian, Edward Ayoub, Akhil Jain, Tapan M. Kadia, Courtney D. DiNardo +13 more

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood(2024)10.1182/blood-2024-211110

N/A

0DataRank · unranked

2 citations

Philip A. Thompson, Jan A. Burger, Musa Yılmaz, Nitin B. Jain, Tapan M. Kadia +23 more

Phase Ib/II Study of CPX-351 in Combination with Venetoclax in Patients with Newly Diagnosed, High Risk Acute Myeloid Leukemia

Blood(2024)10.1182/blood-2024-209558

N/A

0DataRank · unranked

2 citations

Wei‐Ying Jen, Courtney D. DiNardo, Kelly S. Chien, Danielle Hammond, Yesid Alvarado Valero +12 more

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Blood(2024)10.1182/blood-2024-208890

N/A

0DataRank · unranked

1 citations

Kelly S. Chien, Sanam Loghavi, Rashmi Kanagal‐Shamanna, Anuya Natu, Mark E. Gurney +22 more

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood(2024)10.1182/blood-2024-203938

N/A

0DataRank · unranked

1 citations

Hagop M. Kantarjian, Musa Yılmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo +15 more

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood(2024)10.1182/blood-2024-207413

N/A

0DataRank · unranked

1 citations

Jennifer Marvin‐Peek, Marina Konopleva, Gautam Borthakur, Naval Daver, Hussein A. Abbas +21 more

Treatment in Clinical Trials Could Potentially Overcome the Disparity in Outcomes of Patients with Acute Myeloid Leukemia from Disadvantaged Neighborhoods

Blood(2024)10.1182/blood-2024-210779

N/A

0DataRank · unranked

0 citations

Hussein A. Abbas, Guillermo Garcia‐Manero, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo +19 more

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood(2024)10.1182/blood-2024-205186

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado Valero +15 more

Impact of Post-Remission Intensive (IC) Consolidation Chemotherapy Cycles on Overall and Relapse Free Survival after Allogeneic Stem Cell Transplant (SCT) in Patients with Acute Myeloid Leukemia (AML) Receiving IC + Venetoclax

Blood(2024)10.1182/blood-2024-202414

N/A

0DataRank · unranked

0 citations

H. Kantarjian, Wei‐Ying Jen, Gautam Borthakur, Naval Daver, Abhishek Maiti +14 more

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0229

N/A

0DataRank · unranked

15 citations

Jayastu Senapati, Hagop M. Kantarjian, Bofei Wang, Patrick K. Reville, Sanam Loghavi +21 more

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

Blood(2025)10.1182/blood.2024027244

N/A

0DataRank · unranked

13 citations

Bofei Wang, Jennifer Marvin‐Peek, Bin Yuan, Yu-Jen Kuo, Araceli Isabella Garza +17 more

Mini-hyper-CVD plus venetoclax and navitoclax for relapsed/refractory acute lymphoblastic leukemia

Blood Advances(2025)10.1182/bloodadvances.2025016565

N/A

0DataRank · unranked

3 citations

Hagop M. Kantarjian, Nitin B. Jain, Tapan M. Kadia, Jayastu Senapati, Fadi Haddad +12 more

MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

British Journal of Haematology(2025)10.1111/bjh.70171

N/A

0DataRank · unranked

3 citations

Guojun Tang, Eitan Kugler, Jennifer Croden, Koji Sasaki, Alexandre Bazinet +20 more

BET inhibitor-based combinations targeting novel dependencies in MECOM-rearranged (r) AML

Leukemia(2025)10.1038/s41375-025-02842-w

N/A

0DataRank · unranked

2 citations

Warren Fiskus, Christopher P. Mill, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo +13 more

Risk of early death after acute leukemia diagnosis among adolescents and young adults

JNCI Cancer Spectrum(2025)10.1093/jncics/pkaf065

N/A

0DataRank · unranked

2 citations

Clark R. Andersen, Vidya Puthenpura, Nicholas J. Short, Kelly W. Merriman, Mahesh Swaminathan +14 more

Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor

Haematologica(2025)10.3324/haematol.2025.288553

N/A

0DataRank · unranked

2 citations

Sanam Loghavi, Musa Yılmaz, Omer Karrar, Kunhwa Kim, Courtney D. DiNardo +15 more

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Blood Cancer Journal(2025)10.1038/s41408-025-01265-1

N/A

0DataRank · unranked

1 citations

Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Naval Daver +19 more

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome

Haematologica(2025)10.3324/haematol.2024.286559

N/A

0DataRank · unranked

2 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado +19 more

Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations

Blood Cancer Journal(2025)10.1038/s41408-025-01251-7

N/A

0DataRank · unranked

1 citations

Christopher P. Mill, Jessica Piel, Mike Collins, Murphy Hentemann, Branko Cuglievan +18 more

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2020003120

N/A

0DataRank · unranked

182 citations

Guillermo Montalban‐Bravo, Hyunsoo Hwang, Jing Ning, Miguel Franquiz, Rashmi Kanagal‐Shamanna +12 more

Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy‐Based Regimens

American Journal of Hematology(2025)10.1002/ajh.70048

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Nicholas J. Short, Nitin Jain, Ghayas C. Issa, Himachandana Atluri +9 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569

N/A

0DataRank · unranked

174 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Blood Advances(2020)10.1182/bloodadvances.2019001101

N/A

0DataRank · unranked

133 citations

Rashmi Kanagal‐Shamanna, Christopher B. Benton, Caleb A. Class, Kelly S. Chien, Koji Sasaki +17 more

Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality

American Journal of Hematology(2020)10.1002/ajh.26061

N/A

0DataRank · unranked

103 citations

Wei Qiao, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Elias Jabbour +26 more

Mechanistic basis and efficacy of targeting the β-catenin–TCF7L2–JMJD6–c-Myc axis to overcome resistance to BET inhibitors

Blood(2020)10.1182/blood.2019002922

N/A

0DataRank · unranked

73 citations

Warren Fiskus, Christopher P. Mill, Dimuthu Perera, Taghi Manshouri, Bernardo H Lara +18 more

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia

Leukemia(2020)10.1038/s41375-020-0778-0

N/A

0DataRank · unranked

52 citations

Srđan Verstovšek, Jörge E. Cortes, Susan Tse, Yvonne Gasior, Nitin Jain +19 more

Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32623

N/A

0DataRank · unranked

21 citations

Jörge E. Cortes, Keyur P. Patel, Susan O’Brien, Graciela M. Nogueras‐González, Marina Konopleva +11 more

Long‐term results of frontline dasatinib in chronic myeloid leukemia

Cancer(2020)10.1002/cncr.32627

N/A

0DataRank · unranked

34 citations

Jörge E. Cortes, Keyur P. Patel, Lucia Masárová, Gautam Borthakur, Farhad Ravandi +14 more

Clinical value of event-free survival in acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2019001150

N/A

0DataRank · unranked

7 citations

Hagop M. Kantarjian, Vinita Popat, Gautam Borthakur, Guillermo Garcia‐Manero, Marina Konopleva +16 more

Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)

American Journal of Hematology(2020)10.1002/ajh.25991

N/A

0DataRank · unranked

6 citations

Guillermo Montalban‐Bravo, Rashmi Kanagal‐Shamanna, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia +13 more

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.10.27.357111

N/A

0DataRank · unranked

20 citations

Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan +21 more

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7512

N/A

0DataRank · unranked

10 citations

Abhishek Maiti, Farhad Ravandi, Marina Konopleva, Yesid Alvarado, Tapan M. Kadia +14 more

Ten-day decitabine with venetoclax (DEC10-VEN) in AML and high-risk (HR) MDS.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.7519

N/A

0DataRank · unranked

8 citations

Courtney D. DiNardo, Naveen Pemmaraju, Tapan M. Kadia, Caitlin R. Rausch, Kiran Naqvi +15 more

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.04.283598

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Elias Jabbour, Carlos E. Bueso‐Ramos, Yue Wei +14 more

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer Journal(2021)10.1038/s41408-021-00410-w

N/A

0DataRank · unranked

126 citations

Courtney D. DiNardo, Naval Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia +20 more

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Nature Communications(2021)10.1038/s41467-021-22874-x

N/A

0DataRank · unranked

117 citations

Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan +21 more